Sign Out
Iclusig is indicated in adult patients with: chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation. Newly diagnosed Ph+
ALL in combination with chemotherapy.
See Dosage & Administration for the assessment of cardiovascular status prior to start of therapy and Precautions for situations where an alternative treatment may be considered.
Continue with Google